Immunocore has been granted a patent for T cell receptor (TCR) fusion proteins that target the GVYDGREHTV HLA-A*02 complex. The invention includes specific polypeptides and encompasses related polynucleotides, vectors, kits, and pharmaceutical compositions for therapeutic applications. GlobalData’s report on Immunocore gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Immunocore, Peptide pharmacophores was a key innovation area identified from patents. Immunocore's grant share as of July 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
T cell receptor fusion proteins for immune targeting
The granted patent US12065475B2 outlines a T cell receptor (TCR) fusion protein specifically designed to bind to the GVYDGREHTV HLA-A*02 complex. The TCR fusion protein consists of three distinct polypeptides, each defined by specific amino acid sequences (SEQ ID NO:29, SEQ ID NO:30, and SEQ ID NO:28). The patent also includes claims for polynucleotides encoding this TCR fusion protein, as well as kits containing these polynucleotides and vectors for their expression. Additionally, it describes host cells, particularly mammalian cells like Chinese hamster ovary (CHO) cells, that can be used to produce the TCR fusion protein through suitable culturing methods.
Furthermore, the patent details a pharmaceutical composition that incorporates the TCR fusion protein along with a pharmaceutically acceptable carrier, aimed at treating cancer. The methods described include administering the composition to individuals, particularly those with MAGE-A4 expressing cancers and of the HLA-A*02 subtype. The administration routes specified are intravenous or intratumoral injection, and the treatment may be combined with other anti-cancer agents. Notably, the TCR fusion protein may feature glycosylation at a specific site and can be linked through disulfide bonds, enhancing its stability and functionality.
To know more about GlobalData’s detailed insights on Immunocore, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
